On February 15, 2017, Johnson & Johnson received a binding offer from Integra LifeSciences Holdings Corporation to acquire its Codman Neurosurgery business for $1.045 billion in cash. Codman Neurosurgery offers a portfolio of devices focused on advanced hydrocephalus, neuro‑critical care and operative neurosurgery. If the binding offer is accepted, upon closing, Integra will be a leading global provider of neurosurgical products. Cravath is representing Johnson & Johnson in connection with the transaction.
The Cravath team is led by partners Robert I. Townsend III, Damien R. Zoubek and Joel F. Herold and includes associates Cameron S. Stanton, Vince A. Ferrito and Megan E. Fitzgerald on M&A matters; partner Craig F. Arcella on financing matters; partner J. Leonard Teti II and associates Sara L. Lykken and Lingfeng Li on tax matters; partner Jonathan J. Katz and associates Matthew J. Bobby and Peretz Riesenberg on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; and associate Jason M. Sandler on intellectual property matters.